Jazz Pharmaceuticals
As of the edition of 20 October 2026, Jazz Pharmaceuticals runs 33 drugs, 15 of them marketed; it is on route A at 1 target and on route B at 7 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Jazz Pharmaceuticals was renamed in 2012.
The records place 6 company names in this family.
- Celator Pharmaceuticals, Inc.: renamed in 2012
Drugs by status
| Status | Count |
|---|---|
| Marketed | 15 |
| Active | 8 |
| Went quiet | 2 |
| Stopped | 7 |
| Status not established | 1 |
| Total | 33 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cytarabine | none listed | 0 |
| Daunorubicin | none listed | 2 |
| Cannabidiol | Ends 2039 (patent) | 1 |
| Lurbinectedin | Ends 2029 (patent) | 0 |
| Clozapine | none listed | 4 |
| Fluvoxamine | none listed | 3 |
| Oxybate | Ends 2028 (exclusivity) | 2 |
| Zanidatamab | Ends 2036 (computed from the first US licence) | 1 |
| Dordaviprone | Ends 2032 (exclusivity) | 2 |
| Solriamfetol | Ends 2038 (patent) | 0 |
| Defibrotide | none listed | 11 |
| Crisantaspase | none listed | 0 |
| Brincidofovir | Ends 2034 (patent) | 0 |
| Asparaginase erwinia chrysanthemi | Ended 2023 (computed from the first US licence) | 0 |
| Defibrotide sodium | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 7 targets.
All 8 rows on route A or B
In the product8 company-target rows on route A or B; 5 are not shown here, and no score is.
See all 8 targets where Jazz Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 53 trials led
- Cancer: 43 trials led
- Immune system: 19 trials led